|
Name |
2-(4-hydroxybenzyl)quinazolin-4(3H)-one
|
| Molecular Formula | C15H12N2O2 | |
| IUPAC Name* |
2-[(4-hydroxyphenyl)methyl]-3H-quinazolin-4-one
|
|
| SMILES |
C1=CC=C2C(=C1)C(=O)NC(=N2)CC3=CC=C(C=C3)O
|
|
| InChI |
InChI=1S/C15H12N2O2/c18-11-7-5-10(6-8-11)9-14-16-13-4-2-1-3-12(13)15(19)17-14/h1-8,18H,9H2,(H,16,17,19)
|
|
| InChIKey |
MVWHKEGFSBSUSY-UHFFFAOYSA-N
|
|
| Synonyms |
2-(4-hydroxybenzyl)quinazolin-4(3H)-one; CHEBI:68112; CHEMBL1669195; DTXSID201242051; ZINC48603432; AKOS034523849; CCG-331030; 2-(4-Hydroxybenzyl)quinazoline-4(3H)-one; 2-[(4-Hydroxyphenyl)methyl]-4(3H)-quinazolinone; Q27136604; Z666586720; 1260613-04-4
|
|
| CAS | 1260613-04-4 | |
| PubChem CID | 136026468 | |
| ChEMBL ID | CHEMBL1669195 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 252.27 | ALogp: | 1.9 |
| HBD: | 2 | HBA: | 3 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 61.7 | Aromatic Rings: | 3 |
| Heavy Atoms: | 19 | QED Weighted: | 0.737 |
| Caco-2 Permeability: | -4.81 | MDCK Permeability: | 0.00002240 |
| Pgp-inhibitor: | 0.021 | Pgp-substrate: | 0.009 |
| Human Intestinal Absorption (HIA): | 0.019 | 20% Bioavailability (F20%): | 0.817 |
| 30% Bioavailability (F30%): | 0.031 |
| Blood-Brain-Barrier Penetration (BBB): | 0.064 | Plasma Protein Binding (PPB): | 96.04% |
| Volume Distribution (VD): | 0.423 | Fu: | 3.93% |
| CYP1A2-inhibitor: | 0.875 | CYP1A2-substrate: | 0.256 |
| CYP2C19-inhibitor: | 0.881 | CYP2C19-substrate: | 0.063 |
| CYP2C9-inhibitor: | 0.752 | CYP2C9-substrate: | 0.144 |
| CYP2D6-inhibitor: | 0.624 | CYP2D6-substrate: | 0.164 |
| CYP3A4-inhibitor: | 0.355 | CYP3A4-substrate: | 0.466 |
| Clearance (CL): | 6.211 | Half-life (T1/2): | 0.865 |
| hERG Blockers: | 0.129 | Human Hepatotoxicity (H-HT): | 0.29 |
| Drug-inuced Liver Injury (DILI): | 0.956 | AMES Toxicity: | 0.441 |
| Rat Oral Acute Toxicity: | 0.686 | Maximum Recommended Daily Dose: | 0.08 |
| Skin Sensitization: | 0.117 | Carcinogencity: | 0.29 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.122 |
| Respiratory Toxicity: | 0.582 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004931 | ![]() |
0.537 | D0H6TP | ![]() |
0.414 | ||
| ENC001911 | ![]() |
0.429 | D0Y7EM | ![]() |
0.365 | ||
| ENC002149 | ![]() |
0.424 | D00JVR | ![]() |
0.357 | ||
| ENC000858 | ![]() |
0.416 | D0E3SH | ![]() |
0.354 | ||
| ENC003593 | ![]() |
0.414 | D04VKS | ![]() |
0.353 | ||
| ENC001400 | ![]() |
0.410 | D06ZPS | ![]() |
0.352 | ||
| ENC003571 | ![]() |
0.410 | D0S2BV | ![]() |
0.347 | ||
| ENC002970 | ![]() |
0.405 | D0QV5T | ![]() |
0.337 | ||
| ENC005446 | ![]() |
0.400 | D0YB1G | ![]() |
0.326 | ||
| ENC005445 | ![]() |
0.400 | D00LFB | ![]() |
0.326 | ||